Salmonella Vaccine Study in Oxford (SALVO)

You are invited to take part in a study to investigate a new vaccine for invasive non-Typhoid Salmonella (iNTS) disease. The study is being run by the Oxford Vaccine Group which is part of the University of Oxford.

If you are aged 18 to 55 years old, in good health and live in the Oxford area, then you may be eligible to take part. We will provide reimbursement up to a maximum of £585, for your time, inconvenience and travel. The total study participation time is 12 months.

Background

Non-Typhoid Salmonellae are a group of bacteria, that are well known to cause food poisoning throughout the world. However, in certain circumstances they can cause a more serious disease, where Salmonella can spread beyond the gut leading to blood poisoning, and in some cases sepsis and death. This is called invasive non-Typhoid Salmonella (iNTS) disease and is of particular concern in individuals with a weaker immune system. iNTS disease occurs in over half a million people a year, and particularly affects children under 5 years of age in sub-Saharan Africa, where it causes significant disease with over 200,000 cases and 31,000 deaths per year.  Adults can also be affected by iNTS disease, particularly those with HIV, malaria or malnutrition.

Difficulties in diagnosing this infection, antibiotic resistance, as well as transmission via contaminated food and water make the need for an effective vaccine essential.

Study Goals

In this study we are investigating a new vaccine against Invasive Non-Typhoid Salmonella (iNTS). This will be the first time this vaccine will be given to human volunteers. For further information please contact us below to request the Participant Information Sheet or to speak to one of the study team.

We are aiming to confirm the safety and investigate the development of immunity following vaccination.

Study Details

If eligible and if you do decide to take part you will receive either the candidate vaccine or a non-active placebo. Neither you nor research team will know which you have received, until after the trial has finished. This is known as an ‘observer-participant blind’ trial. You will receive 3 doses of either the candidate vaccine or placebo at enrolment then at month  2 and 6. After receiving each dose of vaccine / placebo, you would be required to complete an electronic diary for the next seven days.

The Oxford Vaccine Group, University of Oxford, is based in the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) at the Churchill Hospital, where all study visits / appointments will take place.

Further Information

If you are interested in finding out more, please visit our website: trials.ovg.ox.ac.uk/SALVO where you can access the Participant Information Sheet and register your interest in joining the study.

In addition, if you would like any further information regarding the study please contact us on:

Email: info@ovg.ox.ac.uk   Tel: 01865 611400

Kind Regards,

The Oxford Vaccine Group

This study was funded by the VacciNTS consortium, please find out more information: https://vacc-ints.eu